GENE ONLINE|News &
Week 52 COACH Trial Data Shows Combined Use of TransCon hGH and TransCon CNP Improves Growth and Physical Development in Children with Achondroplasia
New findings from Week 52 of the ongoing COACH clinical trial have provided additional insights into the effects of TransCon® hGH and TransCon® CNP in children with achondroplasia. The data indicate that TransCon® hGH, when used alongside TransCon® CNP, may enhance benefits beyond linear growth in this patient population.
The COACH trial is evaluating the safety and efficacy of these investigational treatments for achondroplasia, a genetic condition characterized by disproportionate short stature. According to the latest results, participants receiving both therapies demonstrated improvements not only in height but also in other areas potentially impacted by achondroplasia. Researchers are analyzing how these combined interventions influence broader aspects of physical development and health outcomes over time.
Newsflash | Powered by GeneOnline AI
Source: GO-AI-ne1
For any suggestion and feedback, please contact us.
Date: April 8, 2026
©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
LATEST
Study Finds Non-Communicable Diseases Consume Large Portion of Household Income Among Elderly in India
2026-04-19
Study Identifies Antiviral Compounds in Egyptian Ziziphus spina-christi Effective Against Respiratory Viruses
2026-04-19
Elevated Fetal Catecholamine Metabolites Linked to Growth Restriction in Sheep Model Study
2026-04-18
EVENT
2026-04-17
AACR Annual Meeting 2026 (Cancer Research & Early-Stage Breakthroughs)
San Diego, California
